Abstract:BackgroundBeckman Coulter developed a fully automated Access HIV Ag/Ab combo assay for the new DxI 9000 Access Immunoassay analyzer that reports separate results for HIV-1 p24 antigen (Ag) and HIV-1/2 antibody (Ab) with a 30 minute time to first result and a sample volume of only 60 μL. Evaluation of the Access HIV Ag/Ab combo assay assessed analytical sensitivity for seroconversion panels, HIV-1 p24 Ag (WHO I.S. NIBSC code 90/636), and HIV-1 and HIV-2 Ag from different viral strains. Clinical specificity and sensitivity of this 4 th generation assay was also assessed.MethodsThirty commercially available seroconversion panels were assessed on Access HIV Ag/Ab combo (3 lots), Abbott Architect HIV Ag/Ab Combo, and Roche Elecsys HIV Duo assays. The HIV-1 p24 Ag analytical sensitivity of the Access assay was performed on dilutions of HIV-1 p24 Ag WHO I.S. prepared in HIV negative human serum and plasma, ranging from 0.1 to 1.0 IU/mL. Fifty positive viral lysates from HIV-1 group M (A-H subtypes, CRF01, CRF02, CRF06, CRF11, CRF14, CRF15, CRF18, CRF36), HIV-1 group O (H and T subgroups), and HIV-2 (groups A and B) were spiked into HIV negative human CPD plasma and tested on both the Access and Architect assays. Clinical sensitivity and specificity were determined for the Access assay using the Architect assay as comparator by testing samples from HIV low risk, high risk and HIV known positive populations at three US clinical laboratories. An HIV 1/2 differentiation assay and HIV-1 RNA PCR were also run to confirm patient infection status.ResultsThe Access HIV Ag/Ab combo assay detected a higher number of bleeds (n=90) than the Elecsys (n = 80) and Architect (n = 77) assays due to earlier Ag detection. The average number of days between positive detection of a bleed previously identified Nucleic Acid Test (NAT) positive compared to these assays was reduced by 1.2 to 1.6 days (Access = 6.8 days; Elecsys = 8.0 days; Architect = 8.4 days). The Access assay also offered a limit of detection for the HIV-1 p24 Ag WHO I.S. between 0.19 and 0.22 IU/mL and a higher sensitivity for HIV-1 p24 Ag compared to the Architect assay: overall median Signal/Cut-Off (S/CO) for the 46 HIV-1 strains = 2.45 with the Access assay when the Architect assay S/CO was normalized at 1.00. HIV-2 strains were not included in this calculation since they were not detected by the Architect assay. A clinical validation study demonstrated 100.0% sensitivity for Access (n= 1,787; 95% CI: 99.8-100.0%) vs 99.8% for the Architect assay (n=1,786; 95% CI: 99.5-99.9%) and 99.7% specificity for Access (n=8,467; 95% CI: 99.5-99.8%) vs 98.8% for the Architect assay (n= 8,467, 95% CI: 98.6-99.0).ConclusionsThe new Access HIV Ag/Ab combo assay demonstrated excellent analytical performances, particularly its high HIV-1 p24 Ag sensitivity, which could help reduce the diagnosis window and thus prevent any delay of treatment for an infected patient. Furthermore, the Access assay showed clinical sensitivity and specificity performance meeting or exceeding that of currently marketed HIV combo immunoassays.

Laboratory-based evaluation of the 4th-generation AlereTM HIV Combo rapid point-of-care test

Evaluation of a point-of-care rapid HIV antibody test with insights into acute HIV symptomatology in a population with low prevalence

Laboratory evaluation of four HIV/syphilis rapid diagnostic tests

Performance Evaluation of the STANDARDTM Q COVID-19 and PanbioTM COVID-19 Antigen Tests in Detecting SARS-CoV-2 during High Transmission Period in Mozambique

Sensitivity and specificity of the new Bio-Rad HIV screening test, Access HIV combo V2

Fourth‐Generation HIV Rapid Tests: Enhanced Sensitivity and Reduced Diagnostic Window for HIV‐1 Primary Infection Screening

B-058 Multicenter Evaluation of the new Access HIV Ag/Ab combo Assay With Highly Sensitive HIV-1 p24 Antigen Detection on the DxI 9000 Access Immunoassay Analyzer

A-365 Rapid HIV testing and confirmation reflex testing integration in Laboratory Information System (LIS) using a point-of-care glucometer

Evaluation of HIV-1 rapid tests and identification of alternative testing algorithms for use in Uganda

Rapid tests should be used with caution for HIV-1 primary infection screening

True and false positive HIV point of care test results in a prospective multinational study of at-risk African women: implications for large-scale repeat HIV testing in HIV prevention programs

Analytical Sensitivity Analysis and Clinical Impact Modeling of Rapigen Rapid Diagnostic Tests for Malaria

Diagnostic performance evaluation of urine HIV-1 antibody rapid test kits in a real-life routine care setting in China

Multisite evaluation of point of care CD4 testing in Papua New Guinea

Development and evaluation of a high-sensitivity RT-PCR lateral flow assay for early detection of HIV-1 infection

A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries

Evaluation of Blood-Based Antibody Rapid Testing for HIV Early Therapy: A Meta-Analysis of the Evidence

Evaluation of rapid diagnostic test kits for detection of Treponema pallidum antibody

Clinic-based evaluation of point-of-care dual HIV/syphilis rapid diagnostic tests at primary healthcare antenatal facilities in South Africa and Zambia

Viral load assay performs comparably to early infant diagnosis assay to diagnose infants with HIV in Mozambique: a prospective observational study

Rapid CD4 cell count determination and Cryptococcus and Histoplasma antigen detection in people living with HIV: Implementation of a package of care strategy in a pilot study, Argentina